Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

KRASG12R mutants in pancreatic cancer develop resistance to daraxonrasib via EGFR/RASWT signaling, enabling effective trametinib-based therapy and extended patient survival.

• Why it matters: Understanding how different KRAS alleles influence resistance mechanisms is crucial for optimizing targeted therapies and improving outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC).
• What they did: Researchers compared resistance pathways in KRASG12D and KRASG12R mutants using daraxonrasib, patient-derived models, and clinical data, revealing allele-specific adaptive responses.
• The result: Findings show KRASG12R tumors rely on EGFR/RASWT signaling upon resistance, which can be targeted with trametinib, leading to significant clinical benefit and prolonged survival in a patient.